State Key Laboratory for Emerging Infectious Diseases, Department of Microbiology and the Research Center of Infection and Immunology, The University of Hong Kong, Hong Kong Special Administrative Region, PR China.
Antiviral Res. 2012 Jan;93(1):144-53. doi: 10.1016/j.antiviral.2011.11.006. Epub 2011 Nov 25.
A naturally-occurring H275Y oseltamivir resistant variant of influenza A (H1N1) virus emerged in 2007, subsequently becoming prevalent worldwide, via an undetermined mechanism. To understand the antigenic properties of the H275Y variant, oseltamivir resistant and susceptible strains of H1N1 viruses were analyzed by hemagglutination inhibition (HI) and microneutralization assays. HI analysis with H1-positive sera obtained from seasonal flu vaccine immunized and non-immunized individuals, and H1-specific monoclonal antibodies, revealed that resistant strains exhibited a reduced reactivity to these antisera and antibodies in the HI assay, as compared to susceptible strains. Neutralization assay testing demonstrated that oseltamivir resistant H1N1 strains are also less susceptible to antibody inhibition during infection. Mice inoculated with a resistant clinical isolate exhibit 4-fold lower virus-specific antibody titers than mice infected with a susceptible strain under the same conditions. Resistant and sensitive variants of 2009 pandemic H1N1 virus did not exhibit such differences. While HA1 and NA phylogenetic trees show that both oseltamivir resistant and susceptible strains belong to clade 2B, NA D354G and HA A189T substitutions were found exclusively, and universally, in oseltamivir resistant variants. Our results suggest that the reduced susceptibility to antibody inhibition and lesser in vivo immunogenicity of the oseltamivir resistant 2008-2009 H1N1 influenza A virus is conferred by coupled NA and HA mutations, and may contribute to the prevalence of this H1N1 variant.
2007 年出现了一种甲型 H1N1 流感病毒的天然存在的 H275Y 奥司他韦耐药变异株,此后通过一种未知机制在全球范围内流行。为了了解 H275Y 变异株的抗原特性,通过血凝抑制(HI)和微量中和试验分析了奥司他韦耐药和敏感株的 H1N1 病毒。用季节性流感疫苗免疫和未免疫个体获得的 H1 阳性血清和 H1 特异性单克隆抗体进行 HI 分析,结果显示耐药株在 HI 试验中对这些抗血清和抗体的反应性降低,而敏感株则不然。中和试验检测表明,奥司他韦耐药 H1N1 株在感染过程中对抗体抑制的敏感性也较低。在相同条件下,接种耐药临床分离株的小鼠的病毒特异性抗体滴度比感染敏感株的小鼠低 4 倍。2009 年大流行 H1N1 病毒的耐药和敏感变异株则没有表现出这种差异。虽然 HA1 和 NA 系统发育树表明,奥司他韦耐药和敏感株均属于 2B 分支,但仅在奥司他韦耐药变异株中发现了 NA D354G 和 HA A189T 取代。我们的结果表明,奥司他韦耐药 2008-2009 年 H1N1 流感病毒对抗体抑制的敏感性降低和体内免疫原性降低是由 NA 和 HA 突变共同导致的,这可能是该 H1N1 变异株流行的原因之一。